¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"primary plot"¿¡ ´ëÇÑ °æºÏ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­³»°úÇб³½Ç »çÀü ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • plot
    ±âÀÔÇÏ´Ù, Á¡À» ÀÕ´Ù, ±¸ºÐÇÏ´Ù
    ±×·¡ÇÁ »óÀÇ Á¡ÀÇ À§Ä¡¸¦ ±×¸®°í ±âÀÔÇÏ´Â °Í.
  • primary vaccination :

    primary's area

    Á¦1¿µ¿ª
    ¿îµ¿°ú °¨°¢ºÎ¸¦ Æ÷ÇÔÇÏ´Â ´ë³ú ÇÇÁú ¿µ¿ª.
  • A alpha primary afferent
    A ¾ËÆÄ ÀÏÂ÷ ±¸½É ½Å°æ
    ±Ù¹æÃß ³»ÀÇ ±Ù ¼¶À¯¿¡ Á¸ÀçÇÏ´Â °¨°¢½Å°æÀÇ Çϳª·Î ¥°a °¨°¢ ½Å°æÀ̶ó°íµµ ÇÑ´Ù. Á÷°æÀº 22§­, Àüµµ ¼Óµµ´Â 120§½ÀÌ´Ù.
  • C primary afferent nociceptor
    C ÀÏÂ÷ ±¸½É¼º Ä§ÇØ ¼ö¿ëü, C ÀÏÂ÷ ±¸½É¼º À¯ÇØ ¼ö¿ë±â
  • early primary closure
    Á¶±â 1Â÷ ºÀÇÕ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • myelinated primary afferent
    ÀÏÂ÷ À¯¼öÃÊ ±¸½É ½Å°æ
  • nociceptive primary afferent
    Ä§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ, À¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive A delta C primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ, ºñÀ¯ÇØ ¼ö¿ë¼º A µ¨Å¸ C ÀÏÂ÷ ±¸½É ½Å°æ
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • primary
    ÀÏÂ÷¼º, ¿ø¹ß¼º, ¿ø¹ß¼ºÀÇ, ÀÏÂ÷, ÀÏÂ÷ÀÇ, ÀÏÂ÷¼ºÀÇ, Á¦ÀÏÀÇ, ÃʱâÀÇ, ¿ø¹ßÀÇ, ÁÖµÈ
    ¹ß»ýµÇ´Â ½Ã±âÀÇ ¼ø¼­¿¡ À־ óÀ½ÀÎ.
  • primary adaptation
    ÀÏÂ÷ ¼øÀÀ, ÀÏÂ÷¼º ¼øÀÀ
  • primary adrenocortical insuffciency
    ¿ø¹ß¼º ºÎ½Å ÇÇÁú ±â´É ºÎÀü
  • primary afferent axon
    ÀÏÂ÷ ±¸½É¼º Ãà»è
  • primary afferent cell body
    ÀÏÂ÷ ±¸½É¼º ¼¼Æ÷ü
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
ÅëÇÕ°Ë»ö ¿Ï·á